William Oh MD

@WilliamOhMD

Deputy Director of Mount Sinai Tisch Cancer Institute and Chief, Hematology/Medical Oncology at Icahn School of Medicine at Mount Sinai. Views are my own.

New York, NY
Vrijeme pridruživanja: rujan 2011.

Tweetovi

Blokirali ste korisnika/cu @WilliamOhMD

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @WilliamOhMD

  1. proslijedio/la je Tweet
    27. sij

    Individualized therapy in metastatic : current options, patient cases, and the latest evidence. CME dinner symposium with , , Matthew R. Smith, MD, PhD, and Evan Y. Yu, MD:

    Poništi
  2. proslijedio/la je Tweet
    31. sij

    "These voting results from a panel of experts can help clinicians and patients navigate controversial areas of advanced prostate management." Quote by Get your copy👉

    , , i još njih 7
    Poništi
  3. proslijedio/la je Tweet
    28. sij
    , , i još njih 5
    Poništi
  4. 26. sij
    Poništi
  5. proslijedio/la je Tweet
    26. sij

    Saddened by real world chart review of pts from 2015-17 era: post-1L erlotinib, only 19% tested for T790M, only 26% got ANY 2L therapy. That's 74% with no additional rx other than 1st EGFR TKI!🤯We must do better.

    Poništi
  6. 21. sij

    Thanks for highlighting this topic! It’s definitely a tricky area with little evidence-based guidance.

    Poništi
  7. 21. sij

    Thanks for exploring our work. It’s always great to speak with you about research!

    Poništi
  8. 21. sij
    Poništi
  9. proslijedio/la je Tweet
    20. sij

    The chalk talk; my own personal two cents... 1. The goal of a chalk talk is not to show how much you know, or to show all the ideas and projects you can think or or actually accomplish

    Prikaži ovu nit
    Poništi
  10. proslijedio/la je Tweet
    16. sij

    It is now interview season! a few thoughts for those going on job interviews for lab based PI positions. 1) Get there the night before the interview, even if no dinner. If no dinner scheduled and you have a friend there, go out for a bite and get the real scoop

    Prikaži ovu nit
    Poništi
  11. proslijedio/la je Tweet

    Here’s the bottom line: $297 million budget boost for in FY 2020 = we are extending paylines and anticipate funding more than 125 additional competing awards this fiscal year than we did in FY 2019. More detail in today’s “Bottom Line” blog post:

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    15. sij

    “Precision oncology has had some major successes.” “And yet, the overall effect of precision medicine on care for patients with cancer has been modest.” ⁦⁩ in ⁦

    Poništi
  13. proslijedio/la je Tweet
    10. sij

    Where are cells in biochemical recurrent disease? Dr.Ken Pienta reviews emerging PET data suggesting that most pts have Lymph Node based disease in early BCR (not bone which is the site for most overt mets) Implications for therapy?

    Prikaži ovu nit
    Poništi
  14. 9. sij
    Poništi
  15. proslijedio/la je Tweet
    7. sij

    The prospective clinical MSKCC NGS cohort is now >50,000 samples sequenced. Thanks to the hundreds of physicians, laboratory technicians, data scientists, nurses and support staff who have made this initiative possible. A few thoughts on what we have learned.

    Prikaži ovu nit
    Poništi
  16. proslijedio/la je Tweet

    Pharma glorifying data mining and "real world evidence" to sidestep clinical trials, and indications of in support w/ drugs approvals by , Front page w/ Hmmm, a lot of here

    Poništi
  17. proslijedio/la je Tweet
    Odgovor korisnicima

    Chest CT screening came onto the scene several years ago with a proven survival benefit but remains woefully underutilitized. Let’s hope in the next decade we see chest CT screening adopted takes its place alongside colonoscopy, mammography, etc as a clear std of care.

    Poništi
  18. 22. pro 2019.

    Still so much to learn re pathogenic germline mutations vs VUS. A sobering article.

    Poništi
  19. 19. pro 2019.

    Honored to host Dr Kanti Rai ⁦⁩ for ⁦⁩ Heme Onc Grand Rounds ⁦⁩! He gave a timely update on CLL including many new therapies.

    Poništi
  20. 17. pro 2019.

    Dr Marcellino will be joining as Assistant Professor next month!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·